Cargando...
Sunitinib resistance in renal cell carcinoma
Of the many targeted therapies introduced since 2006, sunitinib has carved its way to become the most commonly used first-line therapy for the treatment of metastatic renal cell carcinoma (RCC). Despite significant improvements in progression-free survival, 30% of the patients are intrinsically resi...
Guardado en:
| Publicado en: | J Kidney Cancer VHL |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Codon Publications
2014
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5345511/ https://ncbi.nlm.nih.gov/pubmed/28326244 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15586/jkcvhl.2014.7 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|